Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Angiogenesis. Author manuscript; available in PMC 2017 April 1.
Published in final edited form as:
PMCID: PMC4808411

Rasip1 is essential to blood vessel stability and angiogenic blood vessel growth


Cardiovascular function depends on patent, continuous and stable blood vessel formation by endothelial cells (ECs). Blood vessel development initiates by vasculogenesis, as ECs coalesce into linear aggregates and organize to form central lumens that allow blood flow. Molecular mechanisms underlying in vivo vascular ‘tubulogenesis’ are only beginning to be unraveled. We previously showed that the GTPase-interacting protein called Rasip1 is required for the formation of continuous vascular lumens in the early embryo. Rasip1−/− ECs exhibit loss of proper cell polarity and cell shape, disrupted localization of EC-EC junctions and defects in adhesion of ECs to extracellular matrix (ECM). In vitro studies showed that Rasip1 depletion in cultured ECs blocked tubulogenesis. Whether Rasip1 is required in blood vessels after their initial formation remained unclear. Here, we show that Rasip1 is essential for vessel formation and maintenance in the embryo, but not in quiescent adult vessels. Rasip1 is also required for angiogenesis in three models of blood vessel growth: in vitro matrix invasion, retinal blood vessel growth and Directed In vivo Angiogenesis Assays (DIVAA). Rasip1 is thus necessary in growing embryonic blood vessels, postnatal angiogenic sprouting and remodeling, but is dispensable for maintenance of established blood vessels, making it a potential anti-angiogenic therapeutic target.

Keywords: Rasip1, blood vessel, endothelial, lumen, tubulogenesis, angiogenesis, vasculogenesis, vascular, VE cadherin

Graphical abstract

An external file that holds a picture, illustration, etc.
Object name is nihms762110u1.jpg


Formation of a blood vessel network by both vasculogenesis and angiogenesis is essential for embryonic development, as well as for both normal and pathological tissue functions in the adult. Blood vessels are initially composed solely of endothelial cells (ECs), although they come to recruit supportive mural cells. During development, de novo vessel tubulogenesis termed ‘vasculogenesis’ occurs when EC progenitor cells, or angioblasts, assemble at embryonic day 8 (E8.0). Initially, they aggregate into linear cord structures, which then open a central cavity (or lumen). This event allows blood flow, providing oxygen and nutrition to surrounding tissues. Afterwards, new blood vessels sprout from pre-existing blood vessels via a process called ‘angiogenesis’. Growing blood vessels expand their lumens and remodel to form a vascular network and a functional circulatory system. The mechanisms underlying formation of functional lumens during blood vessel development are still not completely understood.

Vascular tubulogenesis

While lumen formation has been extensively studied in vitro using endothelial [13] and epithelial systems [4], the question has recently attracted attention in mammalian in vivo models [57]. Human umbilical vein endothelial cells (HUVECs) in three dimensional (3D) collagen matrices have been used to identify molecules required for lumen formation, including members of the Rho family GTPases such as Cdc42 [2,8]. Since then, entire molecular cascades have been identified in this process [3]. More recently, mammalian vascular lumen formation was shown to fail in portions of the dorsal aortae of the classical mouse vascular endothelial growth factor A (VEGF-A) mutant [9]. In addition, the negatively charged sialomucin podocalyxin (PODXL) at the apical surface of mouse aortic ECs was shown to catalyze lumen initiation via electrostatic repulsion [10].

Cell adhesion, both between ECs and to surrounding extracellular matrix (ECM), is also essential to proper vessel tubulogenesis. Vascular endothelial cadherin (VE-cadherin or VEcad), a cell adhesion molecule, must be removed from the apical surface of ECs to allow lumen opening, however tubulogenesis is impaired in VEcad null mutants [9]. Similarly, loss of β1-integrin in embryonic ECs leads to loss of cell polarity and a block of lumen formation in arterioles [6]. Together these studies have advanced our understanding of vascular lumen formation, however additional molecular regulators of blood vessel formation continue to be discovered.

Rasip1 and GTPases - roles during lumen formation

We showed that Ras interacting protein 1 (Rasip1) is essential for embryonic blood vessel morphogenesis [7]. Rasip1 was initially identified in a yeast two-hybrid screen that identified binding partners of Ras [11]. We showed that Rasip1 was an EC-specific factor throughout embryonic development and into post-natal stages [12]. Deletion of Rasip1 in both frog and mouse caused vascular failure [13]. Rasip1 null ECs exhibit disrupted polarity of junctional complexes, as well as loss of adhesion to ECM. Rasip1 depletion in early blood vessels resulted in discontinuous vascular tubes, blocking blood flow and leading to embryonic lethality by E10.0. Depletion of Rasip1 in ECs cultured in 3D matrices similarly led to failed tubulogenesis. Furthermore, Rasip1 was found to positively regulate the activity of Cdc42 and Rac1, while inhibiting RhoA via the GTPase activating protein (GAP) Arhgap29 during endothelial tubulogenesis. A key role of Rasip1 was shown in control of RhoA signaling and cytoskeleton contractility, which impacted both cell adhesion and EC cell shape, and thereby morphogenesis of blood vessels.

Other groups have identified Rasip1 as a Rap1 effector that controls cell adhesion and junctional stabilization [14]. Rasip1 was shown to signal via Rap1 and its GEF Epac1 and via non-muscle myosin IIB to control cell-cell interactions. This study suggested that Rasip1 primarily regulates the integrity of EC-EC adhesions and blood vessel permeability. More recent studies have confirmed aspects of Rasip1 signaling, placing it upstream of Rap1 and cell-cell junctions, but also identifying it as a key regulator of RhoA signaling via Arghap29 in control of the cytoskeleton and cell adhesion [15,16]. Together, these findings underscore the critical importance of Rasip1 for normal morphogenesis of blood vessels and open questions as to how it regulates formation of vessels across diverse vascular beds.

Here, we show that in addition to its early role in vasculogenesis, Rasip1 is essential for later vessel development, including fetal vascular lumen maintenance, as well as both fetal and postnatal vessel sprouting and remodeling angiogenesis. Using a newly generated Rasip1 conditional allele and a variety of ubiquitous or inducible endothelial Cre driver lines, we deleted Rasip1 at different developmental time points, as well as in quiescent adult vessels. Notably, deletion of Rasip1 from the onset of embryogenesis using Sox2-Cre phenocopied our original global Rasip1 deletion model [7]. We find that Rasip1 is not only required for the cord-to-tube transition during early vasculogenesis, but it is also required for growing blood vessel lumen maintenance and remodeling during later embryogenesis. This requirement, however, does not last into adulthood, as Rasip1 is dispensable in quiescent, established blood vessels. Rasip1 is required, however, for angiogenic sprouting and remodeling, in both growing retinal vessels and in a model of adult angiogenesis. Together, this work extends and confirms our original findings, but also suggests that Rasip1 may be a useful target for development of anti-angiogenic therapies.



Conditional Rasip1 founders were generated by blastocyst injection of ES cells with targeted Rasip1 allele (ID:119405), obtained from KOMP EUCOMM. LacZ and Neomycin resistance cassette were flanked by Flp Recombinase Target (FRT) sites and removed by breeding with Flpe mice to generate Rasip1 floxed allele (Rasip1f/f). Rasip1f/f mice were bred with Flk1-eGFP, Sox2-Cre, Tie2-Cre, Cdh5(PAC)-CreERT2, CAG-CreERT2, Rosa26-YFP, and Rosa26-Tomato [1721]. Primers used to detect floxed, wildtype and mutant alleles were the following sequences: ATGGTATGCCTGCCATTTGT (sense), CGACGTCACTGTGTTCCACT and GGTCCTGTGAAAGAGCAAGC (anti-sense). Western blots were carried out with proteins extracted from mouse tissue using antibodies to Rasip1 (Novus Biologicals NB300-967) and β-actin (Cell signaling 3700).

Histology of mouse embryo and postnatal tissue

Experiments were performed in accordance with protocols approved by UT Southwestern Medical Center IACUC. Mouse embryos and adult tissues were fixed in 4% paraformaldehyde (PFA) in PBS overnight at 4°C. Postnatal retinas were fixed in 4%PFA/PBS for 2hr at room temperature as previously described [22].

Analysis of angiogenesis in the postnatal mouse retina

To delete Rasip1 floxed site in the postnatal mice, tamoxifen (Invitrogen) (3mg of tamoxifen/40g mouse body weight) in corn oil (Sigma) was gavaged to mother mice six times from postnatal day 0 (P0) to P5. Eyes were collected at P6 and fixed in 4% PFA for 3 hr at room temperature. Retinas were dissected and immunostained as whole mount as previously described [23]. For Bromodeoxyuridine (BrdU) labeling, 300μg of BrdU (Invitrogen) was injected into P6 pups by intraperitoneal (IP) injection 2.5h before sacrifice. To visualize vascular lumens, 500μl of 15mg/ml FITC-Dextran (Invitrogen) was injected into left ventricle.

Directed In vivo Angiogenesis Assay

Rasip1f/f; Cdh5(PAC)-CreERT2 mice were treated with tamoxifen (3mg of tamoxifen/40g mouse body weight) at 4 weeks old every other day for two weeks. At 8 weeks old, 20μl silicone cylinders (DIVAA angioreactors) containing basement membrane extract (BME), composed primarily of Laminin I, Collagen IV, and Entactin, with FGF-2 and VEGF (AMS Biotechnology, cat# 3450-048-SK) were embedded subcutaneously (bilaterally) in the dorsal flanks of mice and harvested 2 weeks later. Following the harvest of the angioreactor, the content (BME-blood vessel mixture) was digested according to the manufacture’s instruction. The cells were collected by centrifugation, washed and further incubated with FITC-labeled Griffonia Simplicifolia Lectin I at 4°C overnight. Endothelial cell abundance in the defined volume of matrix was determined by staining cells with FITC-lectin and quantification by fluorometer (excitation 485nm, emission 510nm).

In Situ Hybridization

Whole mount in situ hybridization was performed as previously described [7]. Embryos and retinas were fixed overnight at 4°C and incubated with DIG-labeled RNA probes overnight at 65°C. Tissues were washed with post-hybridization solutions, and then incubated in antibody overnight at 4°C. Color development was carried out using BM purple (Roche). Dig-RNA probes were generated from clones (Open Biosystems): CX40 (BC053054) and Dll4 (BC042497).

Immunofluorescence - sections

Fixed tissues were washed with PBS. For paraffin sections, fixed tissues were dehydrated in series of ethanol washes, incubated in xylene, and then embedded in paraffin. For cryosections, fixed tissues were incubated in 30% sucrose/PBS at 4°C overnight, and then embedded in Tissue-Tek O.C.T. Embedded tissues were sectioned at 10μm by Microtome or Cryostat.

Sections were blocked for 30min. at room temperature in Cas-Block (Invitrogen). Primary antibodies in Cas-Block were incubated at 4°C overnight. Slides were then washed in PBS then incubated in secondary antibody for an hour at room temperature followed by incubation in DAPI. Immunoflorescence stained slides were mounted with ProLong Gold Antifade Reagent (Life Technologies).

Primary antibodies used to recognize the following proteins: PECAM (BD Biosciences 553370), Endomucin (Santa Cruz sc-65495), Rasip1 (Novus Biologicals NB300-967), VE-cadherin (Santa Cruz sc-6458), ZO-1 (Invitrogen 40-2200), Collagen IV (Millipore AB756P), pH3 (Millipore 06-570), Ki67 (Abcam ab15580), Cleaved Caspase 3 (Cell Signaling9661), GFP (Aves GFP-2010).

Immunofluorescence - whole mount

Fixed embryos were incubated in 5% H2O2/ethanol at room temperature for 1 hour, and then rehydrated in series of Ethanol/PBS and 0.1% PBST washes. Embryos were blocked in Cas-Block for 2 hours at room temperature, then incubated in primary antibody diluted in Cas-Block at 4°C overnight. Embryos were washed in PBS, and incubated in Biotin conjugated Secondary antibody diluted in Cas-Block at 4°C overnight. Washed embryos in PBS were then incubated in ABC Elite reagent (Vector Lab), followed by Tyramide solution (Invitrogen TSA kit).

Fixed neonatal retinas and ear tissues were permeabilized in 1%Triton X-100 in PBS, and incubated in primary antibody in 1% Triton X-100 in PBS at 4°C overnight. Tissues were washed with PBS, and incubated in secondary antibody in 1% Triton X-100 in PBS at 4°C overnight. Immunostained retinas were cut and mounted in ProLong Gold Antifade reagent (Invitrogen).

Imaging and quantification

Images were taken with Zeiss Axiovert microscope using DP70 camera (Olympus), LSM 710 Meta Zeiss Confocal microscope, or Zeiss Discovery Stereomicroscope. All data sets were taken from n≥3 biological replicates (embryos or retinas), with n≥5–10 fields of view analyzed. Data are presented as mean ± s.e.m. All statistical analysis was performed using two-tailed, unpaired, Student’s t-test in Graphpad Prism software. P-values lower than 0.05 were considered statistically significant.

Isolectin perfusion

E9.5 embryos were dissected, and yolk sacs were carefully torn for clear view of pumping hearts. 594-Isolectin (Invitrogen) was loaded into a fine needle and injected to left ventricle. After isolectin injection, its mobility through aorta was observed, and pictures were taken by DP70 camera (Olympus).

To visualize postnatal retinal perfusion, 0.0125g FITC-Dextran (Sigma) was dissolved in 1ml of 0.5% PFA/PBS was prepared. 0.5ml of the FITC-Dextran solution was injected into the left ventricle of an anesthetized P6 pup. After 5 min, retinas were dissected out and fixed in 4% PFA for 2 hours at room temperature. The retinas were rinsed with PBS, and then mounted on the slide with ProLong Gold Antifade reagent (Invitrogen).

In vitro sprouting assays

Human umbilical vein endothelial cells (HUVECs) were utilized in 3D collagen matrix assays to induce tubulogenesis to mimic the processes of vasculogenesis or angiogenic sprouting using a defined serum-free system [24]. Four recombinant growth factors (obtained from R&D Systems) were added to 3D collagen matrices each at 200 ng/ml; fibroblast growth factor-2 (FGF-2), stem cell factor, interleukin-3 and stromal-derived factor-α. The culture media was Medium 199 with a 1:250 dilution of reduced serum supplement II (containing insulin) [8] and FGF-2 (40 ng/ml). ECs were treated with siRNAs directed to Rasip1, Arhgap29 (or both) versus control and then these assays were performed for 16 to 72 hr. EC tube formation was quantitated by tracing lumen areas using Metamorph software and EC tip cell numbers were quantitated by identifying elongated ECs with finger-like projections in light microscopic images. siRNAs from Ambion were: Control (AM4637) Silencer Select Negative Control #2;Rasip1 (s29763) 5′-CGAGCUGUUCAAAUCCGAA-3′, Arhgap29 (s485) 5′-GACCAAGGCUAAAACGAAU-3′.

Permeability assay

0.5% Evans Blue (Invitrogen) solution in PBS was injected in the tail vein of the mice. To measure permeability at skin surface, 50ng of VEGF in 500μl of PBS or PBS alone were applied by intradermal injection. After 30 min, the mice were sacrificed and organs of interest were collected and weighed. Each tissue samples were incubated in 500μM formamide at 55°C overnight. Concentration of dissolved Evans Blue in formamide was measured by spectrophotometer (NanoDrop2000C, Thermoscientific) with absorbance at 610 nm.


Rasip1 is essential for initial blood vessel formation

We previously showed that Rasip1 global null (Rasip1−/−) mouse embryos fail to form functional vascular tubes during initial blood vessel formation (or vasculogenesis), around embryonic day (E) 8.5 [7], resulting in 100% lethality. To test this requirement during angiogenesis and adult vessels, we generated conditional Rasip1 (Rasip1f/f) mice, using ES cells from the Knockout Mouse Project Repository (KOMP). We then tested deletion of Rasip1 ubiquitously by crossing Rasip1f/f mice to Sox2-Cre, and conditionally in ECs using Tie2-Cre or Cdh5(PAC)-CreERT2 (Fig. 1A).

Figure 1
Rasip1 is required for dorsal aorta lumen formation during vasculogenesis

In the presence of Cre, exon 3 of Rasip1 is deleted in Rasip1f/f mice, resulting in a nonsense mutation (Fig. S1). During generation of the transgenic allele, a cassette containing the LacZ reporter and neomycin positive selection gene (LacZNeo) was inserted between Rasip1 exons 2 and 3, flanked by FRT site sequences. β-galactosidase staining of embryos containing this cassette showed EC specific expression at E8.5 (Fig. 1B–C). Rasip1LacZNeo/+ and Rasip1LacZNeo/LacZNeo mice were bred to a Flk1-eGFP transgene to help visualize ECs. Rasip1LacZNeo/LacZNeo embryos displayed narrower dorsal aortae at E8.5, as seen in whole mount and cross sections of the embryos, suggesting that insertion of the LacZ and Neo genes may disrupt Rasip1 expression (Fig. 1D–G). Closer inspection of the vessels revealed failed lumen formation (Fig. S2) and an inability to polarize the tight junction marker ZO-1 away from the apical membrane (Fig. S2F). These data indicate that this mouse line recapitulates the global Rasip1 knockout.

To completely delete Rasip1, the LacZNeo cassette was excised by crossing the mice to FLP recombinase transgenic mice, leaving behind the floxed allele (Rasip1f/f). Rasip1f/f was then crossed to Sox2-Cre to delete Rasip1 ubiquitously throughout the epiblast. This resulted in embryos with vascular tubulogenesis failure identical to that seen in our previously generated Rasip1 global null mouse [7] (Fig. 1H–O). Antibody staining for Rasip1 showed complete loss of Rasip1 protein when using Sox2-Cre (Fig. 1H–K). Staining for VEcad revealed that ECs do not segregate the apical and lateral membranes properly, as adhesions are not cleared away from the apical membrane (Fig. 1L–O). In situ hybridization for the gene connexin 40 (CX40), expression of which is dependent on normal blood flow [25], showed that Rasip1 is also necessary for arterial fate in the aortae, as previously shown (Fig. S3) [7].

To investigate the function of Rasip1 in the vasculature during vasculogenesis, Rasip1f/f mice were crossed to Tie2-Cre, which reportedly expresses Cre recombinase in angioblasts and in ECs [26]. We found that some, but not all Rasip1f/f;Tie2-Cre embryos displayed tubulogenesis defects at E8.5 (Fig. 2). This was in contrast to the fully penetrant and global vascular failure seen in Rasip1f/f;Sox2-Cre and Rasip1−/− mice, which always displayed occluded and discontinuous lumens at the onset of vasculogenesis. Generally, wild type (WT) E8.25–8.5 (5–8 somite stage) control embryos displayed patent dorsal aortae with continuous lumens (Fig. 2A,D). By contrast, Rasip1f/f;Tie2-Cre embryos produced heterogeneous and mosaic lumen phenotypes in the dorsal aortae. About half of the embryos visually displayed occluded vessels (n=10) (Fig. 2B,E), while the other half had normal dorsal aortae with open lumens (Fig. 2C,F). Of all of the embryos observed in cross section, about 40% of the aortae (n = 10) had failed lumen formation.

Figure 2
Rasip1 is required to maintain dorsal aorta lumens and allow circulation

Of note, Tie2-Cre is also expressed in hematopoietic cells, however we did not observe defects in this cell type upon Rasip1 Tie2-Cre deletion. This is likely because Rasip1 is not expressed in early blood cells.

Rasip1 deletion efficiency with different Cre lines

The variable observed phenotypes led us to examine efficiency of Rasip1 protein deletion in ECs using immunofluorescent staining. Cre expression, assessed with the Rosa26-YFP reporter, was clearly detected in early angioblasts at E8.0 (0–2 somite stage) (Fig. S4), suggesting gene deletion by Cre expression initiated in EC precursors. Antibody staining for Rasip1, however, unexpectedly revealed that Rasip1 protein was still present in PECAM and endomucin positive ECs (double stained, hereby designed as ‘PE’) in Rasip1f/f;Tie2-Cre embryo at 5s (Fig. 2G–H,K–L). By 10s, however, Rasip1 protein was detectable in only 38% of embryonic ECs (Fig. 2I–J,M–O). In embryos with fully deleted Rasip1, failed tubulogenesis was observed in aortic ECs and tight junction molecules Claudin5 and ZO-1 and adherens junction molecule VEcad failed to clear from the apical membrane (Fig. S5A–L), suggesting polarity defects. However, the apical marker Podxl retained its normal localization at the apical membrane (Fig. S5M–R). Together, these findings suggest that the Tie2-Cre transgene only deletes Rasip1 prior to lumen opening in approximately 50% of Rasip1f/f;Tie2-Cre embryos, preventing lumen formation during vasculogenesis.

Rasip1 is required for embryonic vessel maintenance

Although some Rasip1f/f;Tie2-Cre embryos did not exhibit vascular defects before E8.5, all embryos older than E8.75 displayed profound vascular defects. Anti-PECAM whole mount staining revealed that 100% of Rasip1f/f;Tie2-Cre dorsal aortae at E8.75 had a constricted appearance and discontinuous lumens (Fig. 2P–Q). Discontinuous and constricted vascular lumens in aortae were shown in transverse sections through the embryonic trunk (Fig. S6C–D). In addition, arterial endothelial fate was affected as evidenced by loss of CX40 gene expression in dorsal aortae of Rasip1f/f;Tie2-Cre embryos (Fig. 2R–S). 100% of Rasip1f/f;Tie2-Cre embryos displayed hypoplasia by E9.0 (Fig. S6B). To further determine functionality of blood vessels upon Rasip1 deletion with Tie2-Cre, we assessed blood circulation by injecting fluorescent Isolectin B4 (IB4) into the pumping heart of E9.5 mice. Injected IB4 in WT embryos rapidly traveled through the dorsal aortae and reached the caudal tail (Fig. 2T). By contrast, IB4 in the Rasip1f/f;Tie2-Cre mutant embryos failed to circulate properly down the aortae and remained in the heart despite a normal heartbeat rhythm and strength (as per visual observation) (Fig. 2U). These results suggest that deletion of Rasip1 using Tie2-Cre blocks blood circulation in the developing embryo due to occluded vessels.

Furthermore, these results show that the vessel failure phenotype in Rasip1f/f;Tie2-Cre embryos is distinct from Rasip1f/f;Sox2-Cre or Rasip1−/− embryos. In Rasip1f/f;Tie2-Cre embryos, residual Rasip1 protein remains in ECs due to inefficient Rasip1 deletion prior to lumen formation. This allows about half of the embryos to undergo normal tubulogenesis in the dorsal aortae. 50% of the embryos formed vascular lumens at stages E8.0–8.5 (1–8s), but 100% of the embryos display occluded aortic lumens by E9.0. Together, these data suggest that embryonic vessels collapse after Rasip1 deletion, even if they initially open lumens. This indicates that Rasip1 is required to maintain vascular lumens during early development.

Rasip1 is required for mid-gestation embryonic angiogenesis

Because all Rasip1f/f;Tie2-Cre mutant embryos die by E10.5, Rasip1 function in later blood vessel lumen formation or maintenance cannot be assessed. To determine if Rasip1 is important for vascular development after early vasculogenesis, Rasip1 was deleted using the Cdh5(PAC)-CreERT2 driver line [27]. This line expresses Cre recombinase under the control of the VE-cadherin promoter in an inducible manner. We first induced at E9.5 by tamoxifen gavage, and assayed vascular defects at E12.5 (Fig. 3). We found that Rasip1f/f;Cdh5(PAC)-CreERT2 embryos developed hemorrhages and died soon after vascular defects developed (Fig. 3A–B). We visualized vessels in the limb of Rasip1f/f;Cdh5(PAC)-CreERT2 embryos, using whole mount anti-PECAM staining, and found the limb vascular plexus disorganized with thin and disconnected vessels (Fig. 3C–F). Cross sections revealed that a number of vessels did not display open lumens (Fig. 3G–L), while others were swollen and enlarged (larger trunk vessels did not show obvious collapse). Quantification of vessel diameter revealed that 20% of capillaries failed to develop or maintain lumens (Fig. 3M). These results indicate that Rasip1 is required not only for the development and maintenance of vessels that form during vasculogenesis, but also for angiogenic expansion and remodeling that occurs within tissues at midgestation.

Figure 3
Rasip1 is required for blood vessel maintenance and later embryonic vascular lumen formation

Rasip1 is required for neonatal retinal vessel outgrowth

To study whether Rasip1 is required in blood vessels in other tissues and at other stages, we examined angiogenic sprouting during retinal vessel growth in postnatal mice. In situ hybridization of Rasip1 mRNA confirms restricted expression of Rasip1 in retinal blood vessel endothelium (Fig. S7A). Therefore, deletion of Rasip1 using the ubiquitous and inducible CAG-CreERT2 driver line should produce primarily EC autonomous defects after administering tamoxifen [18]. We carried out daily tamoxifen treatment of Rasip1f/f;CAG-CreERT2 or Rasip1f/f mice from postnatal day (P) 0 to 5, and retinas were analyzed at P6 (Fig. S7B). Vessels were visualized using isolectin B4 staining (Fig. S7D) and efficiency of Cre recombinase expression was examined using Rosa26-YFP (Fig. S7E). Following tamoxifen application, over 80% of retinal vessel ECs were YFP+ (Fig. S7C–E), indicating significant deletion of Rasip1 was achieved in this vascular bed.

To assess the requirement of Rasip1 in angiogenesis, neonatal retinal vessels were examined for possible defects in vessel growth, remodeling, or lumen formation. Blood vessels in the retina grow strictly by angiogenesis, by way of sprouting and remodeling. Capillaries first enter the retina from the optic disc and then extend outward radially in a planar fashion, atop the retinal tissue that abuts the vitreous cavity [28].

Analysis of retinas following Rasip1 deletion showed significantly decreased blood vessel growth from the center of the retina compared to controls (Fig. 4A–C). Quantification of the distance between the optical disc and vascular tip showed a 23% reduction in vessel growth (Fig. 4C). To determine whether reduced outgrowth in Rasip1 deficient vessels resulted from decreased proliferation of ECs, BrdU incorporation was carried out. The number of BrdU positive ECs in Rasip1 mutant retinal vessels was equivalent to the control retina (Fig. 4D–F), suggesting that Rasip1 deletion does not affect EC proliferation, consistent with our previous findings [7]. It is known that formation of filopodia at growing tip cells is required for angiogenic sprouting [29]. The number of filopodia and sprouts were not significantly affected by Rasip1 deletion (Fig. 4G–I). However, Rasip1 depletion led to increased vascular density within the capillary plexus (Fig. 4J–L). Vessel bed density (area) increased by 18.5% (P value =0.0025) (Fig. 4L). Close inspection of the vessels revealed that ECs were rounded with nuclei exhibiting decreased length (54% shorter) (Fig. 4M–O). Based on these results, we propose that vessel outgrowth is reduced in the absence of Rasip1, likely due to defects in EC morphology and failure of capillary plexus remodeling.

Figure 4
Rasip1 is required for retinal vessel angiogenesis

Rasip1 deficiency causes blood vessel instability and angiogenesis defects

In addition to increased vascular density, Rasip1 deficient retinal vessels also displayed poorly organized capillary plexuses. To examine vessel stability in Rasip1 deficient plexuses, type IV collagen was examined to visualize EC tracks. We found that in regions of Rasip1 deletion, anti-collagen IV staining was observed to extend beyond IB4 positive blood vessels at the vascular front (Fig. 5A–C″). We speculated these areas to represent residual blood vessel basement tracks left by retracting tip vessels, suggesting failure in stabilization of remodeling vessels in the absence of Rasip1. Rasip1 deficient vessels also often displayed thin and elongated angiogenic sprouts at the periphery of the vascular front (Fig. 5D–F).

Figure 5
Rasip1 is required for blood vessel stability

In WT vessels, two sprouts develop at the leading edge of the plexus and fuse by anastomosis to become part of the vascular plexus [3032]. In Rasip1 deficient vessels, however, the sprouts appeared to lose the ability to fuse with neighboring sprouts. In addition, vascular stability was disrupted as hemorrhages and extravascular blood were observed (data not shown). This data suggests that Rasip1 is likely necessary for anastomosis and to restrain the length of angiogenic sprouts.

Rasip1 is required for neonatal retinal vessel lumen formation

During vasculogenesis, Rasip1 was identified as a critical factor for EC tubulogenesis. To examine whether Rasip1 also controls lumen formation during angiogenesis, fluorescein isothiocyanate (FITC)-dextran was injected into the vasculature by perfusion. In WT retinas, dextran traveled throughout the capillaries and perfused the entire retinal vascular bed (Fig. 5G). This suggested that most retinal vessels are lumenized. By contrast, Rasip1 depleted vessels exhibited regions with no dextran at the leading edge of the vascular front (Fig. 5H). Quantification of the dextran perfused area in growing vessels showed a 72% reduction in the mutants (Fig. 5I). Although dextran did not reach the edge of the vascular bed, it was present at the center of the retina. Altogether, these data suggest that Rasip1 is required for proper lumen formation and vascular plexus remodeling.

Rasip1 deletion in adult blood vessels

To examine whether Rasip1 is required in established adult mouse blood vessels, we deleted Rasip1 in 8 week old mice using the inducible Cdh5(PAC)-CreERT2. We injected Tamoxifen every other day for two weeks to effectively delete Rasip1. We then confirmed Rasip1 deletion by polymerase chain reaction (PCR) using genomic DNA to detect the deleted Exon 3 allele (Fig. S8A). To confirm the deletion of exon3 from Rasip1 transcripts, exon 2 and 3 loci were examined from cDNA generated from tamoxifen induced adult Rasip1f/f;Cdh5(PAC)-CreERT2 lungs. While exon2 was detected in Rasip1f/f;Cdh5(PAC)-CreERT2, exon 3 was significantly reduced (Fig. S8B). To confirm Rasip1 protein depletion, Western blot analysis was performed. As expected, Rasip1 level was significantly decreased in Rasip1 deficient lungs [11] (Fig. S8C). To visualize the Rasip1 deletion efficiency, Rasip1f/f;Cdh5(PAC)-CreERT2 mice were bred with Rosa26-Tomato reporter mice. After tamoxifen induction, most ECs examined in Rasip1f/+;Cdh5(PAC)-CreERT2 and Rasip1f/f;Cdh5(PAC)-CreERT2 mice expressed tomato fluorescence in the ear skin vasculature (Fig. S8D). In addition, immunofluorescent staining for Rasip1 in the endothelium lining the adult dorsal aorta, showed that Rasip1 was not detected in Rasip1f/f;Cdh5(PAC)-CreERT2 ECs (Fig. 6A–B).

Figure 6
Rasip1 is dispensable for adult vessel maintenance

Rasip1 dispensable in established adult blood vessels

Rasip1f/f;Cdh5(PAC)-CreERT2 mice were grossly normal and healthy after tamoxifen treatment. To examine possible vascular defects, ear skin vessels were immunostained with anti-PECAM. Rasip1 depleted vasculature appeared normal and morphologically indistinguishable from control vessels (Fig. 6C–D). Previously, Rasip1 has been shown to be necessary for blood vessel permeability in ECs in vitro [14,15]. To test permeability in Rasip1 depleted quiescent vessels in vivo in adult mice, we injected Evans Blue dye to assess vessel “leakiness”. Evans Blue dye binds to albumin, a serum protein that is impermeable to the endothelium under non-stimulated conditions. Under stress conditions or growth, blood vessel ECs partially lose close adhesion contacts increasing blood vessel permeability to small proteins such as albumin [33]. Injection of VEGF stimulates EC permeability [34]. As expected, subcutaneous injection of VEGF into mice perfused with Evans Blue in the serum caused the blue dye to permeate into the surrounding injection site (Fig. 6E). Injection of PBS, by contrast, did not stimulate perfusion of Evans Blue at the injection site, confirming that VEGF increases vascular permeability and allows serum proteins to leak between ECs. Interestingly, although Rasip1 was previously shown to increase vascular permeability in vitro, quiescent Rasip1 mutant vessels did not show increased leakage in the lungs, liver, kidney, or skin, either when stimulated by VEGF injection and under non-stimulated conditions (Fig. 6F–G). This experiment indicates that Rasip1 may not measurably regulate vascular permeability in adult mouse vessels, in vivo.

Rasip1 is required for angiogenesis in vivo and in vitro

We next confirmed that Rasip1 is required for lumen formation in cultured human ECs. We also assayed the role of Rasip1’s binding partner Arhgap29. As previously reported [7], after reduction of Rasip1 or Arhgap29 in HUVECs with siRNA, ECs assembled into cords but failed to develop lumens compared to controls (Fig. S9A–B,E). Reduction of both Rasip1 and Arhgap29 led to the same phenotype of EC cord structures that lacked lumens (Fig. S9D–E).

Similarly, loss of Rasip1 and Arhgap29 led to defects in angiogenic sprouting in vitro. We performed angiogenesis assays where HUVECs were plated atop VEGF-containing collagen, into which they sprouted. Interestingly, although lumen formation was reduced after reduction of Rasip1, Arhgap29, or both (Fig. 7A–E), the distance of cell invasion into the collagen was not affected (Fig 7F). This suggests that Rasip1 and Arhgap29 are not necessary for invasion into collagen. To determine whether Rasip1 or Arhgap29 affects tip cell number in the invading sprouts, we quantified the number of tip cells after 16 or 72 hour of culture by examining cross-sections. After treatment with control siRNA, around 25 tip cells at the end of angiogenic tips developed after 16 hours (Fig 7G). After 72 hours, only 5 or fewer tip cells were clearly discernible. By contrast, after Rasip1 or Arhgap29 reduction, the number of tip cells remained similar to controls at 16 hours, but after 72 hours the number of tip cells remained high and depleted less over time. Depletion of Rasip1 and Arhgap29 did not change the number of tip cells between 16 hours and 72 hours, however these were long and thin, similar to tip cells observed in retinal vessels following Rasip1 depletion. Together, this suggests that in addition to controlling vessel tubulogenesis, Rasip1 and Arhgap29 signaling pathways control tip cell behavior during angiogenic sprouting.

Figure 7
Rasip1 is required for angiogenesis in human ECs and in adult subcutaneous vasculature

Rasip1 is required for adult angiogenic vessel growth in vivo

To investigate whether Rasip1 is required for angiogenesis in adult mouse vessels, similar to neonatal retinal vessels, we examined vessel sprouting in tamoxifen treated Rasip1f/f;Cdh5(PAC)-CreERT2 and control mice, using Directed In Vivo Angiogenesis Assay (DIVAA) angioreactors (Fig. 7H). This assay consists of silicon tubes containing basement membrane extract mixed with fibroblast growth facter-2 (FGF-2) and VEGF, which are implanted subcutaneously and allow assessment of growing vessels, as previously shown [3537]. In this assay, host blood vessels sprout into the implant, providing a means to measure angiogenesis in vivo.

After two weeks of vessel growth, angioreactors were removed from the mice and evaluated for changes in the degree of angiogenesis. ECs expressing Cre recombinase were visualized by using Rosa26-Tomato reporter mice. Vessel growth was observed in angioreactors (Fig. 7I–J), first by visualization of the tomato-labeled vessels (indicating Rasip1 deleted ECs), which showed that Rasip1 depletion decreased EC invasion into the angioreactors (Fig. 7I′,J′). In addition, the total number of ECs invading the angioreactors was found to be significantly reduced in Rasip1f/f;Cdh5(PAC)-CreERT2 mice compared to those in control mice, as determined by subsequent EC isolation and staining with FITC-lectin (Fig. 7K). These results indicate that Rasip1 is required for growth factor (FGF/VEGF) induced angiogenesis from adult vessels.


In this study, we examined the role Rasip1 during vasculogenesis, angiogenesis, and maintenance of ECs in vivo, using a Rasip1 conditional knockout mouse model. In a previous study, we identified Rasip1 as a critical regulator of blood vessel tubulogenesis in the developing mouse embryo [7]. Here, we show that Rasip1 is essential for embryonic angiogenesis and vessel maintenance, after initial tubulogenesis. Tie2-Cre or inducible Cdh5(PAC)-Cre deletion of Rasip1 in embryonic or perinatal vessels, after lumen formation, caused severe defects in angiogenesis, maintenance of EC lumens and vascular remodeling. Interestingly, we found that Rasip1 was dispensable for established blood vessels. Ablation of Rasip1 in ECs of adult mice did not lead to vascular defects. However, nascent vessels that form via sprouting or remodeling angiogenesis, require Rasip1 both in the postnatal retinal vasculature and in growing subdermal adult vessels (DIVAA). Together, our findings suggest that Rasip1 is essential for growing vessels, but not for quiescent blood vessel stability or function.

Rasip1 is required for lumen formation

We previously showed that Rasip1 is critical for EC tubulogenesis during vasculogenesis [7]. This idea was challenged by Wilson et al., who proposed that Rasip1 is not required for de novo lumen formation, as patent lumens were observed in their Rasip1−/− mice [14]. Using a second, independently generated conditional ablation mouse model (KOMP), we confirm here our initial findings that Rasip1 is indeed essential to formation of continuous, functional EC tube formation during vasculogenesis.

Using a newly generated Rasip1 floxed allele, Sox2-Cre driven Rasip1 deletion phenocopied previously observed blood vessel tubulogenesis defects. Global and early Rasip1 deletion results in failure of endothelial cell-cell adhesions to organize peripherally and clear from the apical membrane. These junctional failures result in consequent inappropriate stitching of ECs together and prevention of continuous lumen formation (Fig. 8A). This phenotype was also observed in embryos that contain a LacZNeo cassette between the second and third exon, which interrupts the Rasip1 coding region.

Figure 8
Rasip1 regulates adhesion polarity and cell shape to control lumen formation and blood vessel morphogenesis

These results support our previous findings that Rasip1 is essential for vascular tubulogenesis. A few studies have shown that Rasip1 is necessary to maintain the integrity of EC cell-cell adhesions in vitro [12,7,14]. In these studies, reduction of Rasip1 resulted in jagged and permeable adhesions. Rasip1 was found to control cell adhesions by mediating activated Rap1 and by inhibiting RhoA via the GAP Arhgap29. Previously, these signaling cascades have been shown to regulate actomyosin contractility to maintain stability of cell-cell adhesions and prevent them from becoming jagged and active [38]. It is likely that the function of Rasip1 identified in some of these studies, in organizing maturing focal adhesion junctions, may reflects its role in reorganizing adhesions within vascular cords. ECs need to rapidly clear cell adhesions from the apical domain of vascular cords, while maintaining lateral cell-cell junctions, thereby forming a single lumen that allows blood flow. Similar to Rasip1 control of adhesion organization via Rap1-RhoA signaling, Rasip1 is likely using these same mechanisms to organize adhesions between ECs in vascular cords to drive lumen formation between adhesions.

Rasip1 is required for angiogenesis

Following vasculogenesis, blood vessel beds expand via angiogenesis. Angiogenesis in adults has been extensively studied because of the role it plays in many pathologic conditions such as cancer, diabetic blindness, age-related macular degeneration, and rheumatoid arthritis. From these studies, a wealth of mechanisms, signaling pathways and different molecules have been revealed to regulate angiogenesis. While roles for Rasip1 in EC behavior were previously tested in vitro showing its requirement for EC coalescence, cell motility, and migration, we speculated that Rasip1 was likely required for vascular events inherent in angiogenesis [12].

To test for an angiogenic role for Rasip1, we used three different model systems: neonatal retinal vessel angiogenesis, adult subcutaneous vessel angiogenesis, and angiogenesis in 3D collagen matrix. In the first model, we showed that Rasip1 deficient retinal vessels displayed angiogenic defects, including significantly reduced vessel outgrowth and higher vascular density (Fig. 8B). Cells within the vascular plexus displayed a rounded cell morphology, characteristic of cells with high internal contractility. We propose that absence of Rasip1 leads to high RhoA activity, causing remodeling defects that lead to higher plexus density and reduced vessel outgrowth. Work by Post et al. 2013 and Xu et al. 2011 demonstrated that Rasip1 suppresses EC contractility by suppressing RhoA-actomyosin signaling. RhoA activates myosin to enhance actomyosin contractility of the actin cytoskeleton and therefore internally contract the cell. By inhibiting RhoA, and therefore myosin, Rasip1 eases the tension produced by internal actin contraction allowing the cells to relax and elongate. This mechanism likely allows vessels in the retina to extend and form a proper vascular plexus.

Rasip1 ablation impairs angiogenic tip cells and lumens

Tip cells in the retina, however, displayed a different effect upon loss of Rasip1. Elongated sprouts were often found at the edges of Rasip1 depleted plexuses, appearing to fail to make connections with neighboring sprouts. A similar phenotype was previously reported in macrophage specific Notch1 deficient mice. In this study, it was shown that macrophages interact with Dll4 positive tip cells and activate Notch signaling to promote anastomosis [39]. Furthermore, reduction of Rasip1 or its binding partner Arhgap29 caused in vitro generated sprouting vessels to maintain excess numbers of tip cells. This phenotype is likely associated with Notch-Dll4 signaling as mutants lacking Notch maintain high numbers of tip cells [40]. The possibility that impaired Notch signaling could cause failure of tip cell-stalk cell maintenance and anastomosis in Rasip1 depleted retinas, resulting in elongated vessels, warrants further investigation.

While our understanding of lumen formation during angiogenesis is still primitive, we asked whether Rasip1 plays a role in tubulogenesis of sprouting vessels in the retina. Since Rasip1 was known to be required for EC tubulogenesis [7], we tested for the presence of functional vessels by injecting fluorescent labeled dextran into control and Rasip1 deficient vessels to visualize lumens and assess patency. Dextran was detected in both control and Rasip1 mutant mice, but retinal vessels from Rasip1 mutant mice displayed perturbed and discontinuous lumens around the retinal plexus periphery, where newly forming vessels are located, suggesting that Rasip1 is required for proper angiogenic lumen formation.

Rasip1 is dispensable in adult blood vessel maintenance

The importance of vascular maintenance has received attention as clinical treatments for vascular diseases have failed due to an interruption in vessel integrity [41]. Disruptions in signaling pathways involved in vessel maintenance cause the breakdown of vessels and impair vascular homeostasis. Signaling pathways such as the VEGF, Tie2, PDGF, and Notch are important for junction stabilization and vessel integrity. Interruption of these pathways results in vascular abnormalities and malformations, causing severe clinical conditions. As Rasip1 is essential for embryonic tubulogenesis and angiogenesis, we expected that Rasip1 deletion in the adult would cause severe vascular problems. However, endothelial specific deletion of Rasip1 caused no obvious abnormalities in the vasculature of adult mice. Rasip1 deficient mice appeared healthy and lived long term without obvious chronic health conditions, even though the mice demonstrated robust deletion of Rasip1 protein and mRNA and Cre-mediated recombination. Proliferation, morphological appearance, and vascular permeability were not affected by absence of Rasip1. These data suggest Rasip1 may be dispensable in established, quiescent vessels.

Previously, it was demonstrated that Rasip1 is required for maintenance of EC permeability in cultured ECs [15,14,16]. Rasip1 was shown to function as a Rap1 effector to suppress RhoA activity, and thereby inhibits formation and contraction of stress fibers attached to VE-cadherin based adherens junctions. Rasip1 depletion leads to discontinuous junctions that allow increased cell permeability. These studies utilized Electrical Cell Impedance Sensing (ECIS) to measure the passage of current across an endothelial layer in vitro. We show that at least in vivo no gross changes in vascular permeability were detected in adult vessels in Rasip1 deficient mice using an Evans Blue assay, which measures the passage of albumin through blood vessels. These results are in contrast to previous in vitro findings. More sensitive in vivo permeability assays may also be necessary to detect the passage of small molecules across the endothelium in blood vessels following Rasip1 deletion. Additionally, further investigation will be required to determine if Rasip1 influences vascular permeability in response to other permeability stimulators such as histamine or pathological conditions. Alternatively, Rasip1 may not regulate junction integrity in quiescent ECs, or do so in parallel with other factors. However, our observations suggest it may primarily regulate junction stability in actively growing vessels, during both vasculogenesis and angiogenesis, as seen in retinal sprouting and remodeling vessels and throughout development.


In this study, Rasip1 is identified as a critical factor regulating tubulogenesis and overall blood vessel morphogenesis, during vasculogenesis and angiogenesis in vivo, using Rasip1 conditional gene ablation. Deletion of Rasip1 in embryonic vessels that form by vasculogenesis caused failure in endothelial tubulogenesis, as previously shown [7]. We also show that in embryonic vessels, Rasip1 is required for embryonic lumen maintenance, even after initiation of lumen formation. Rasip1 loss after lumen formation caused collapse of new vessels resulting in vessel instability. During angiogenesis, Rasip1 depletion caused significant abrogation of angiogenic expansion, due to failure of vessel remodeling. Rasip1 removal also affected angiogenesis in adult mice, as shown in DIVAA experiment. However, Rasip1 depletion in established adult vessels did not cause defects in vessel lumen maintenance. Together, these findings suggest that Rasip1 is critical for angiogenesis in the developing vasculature, but not for maintenance of stable blood vessels.

Anti-angiogenesis research has received clinical attention, however despite rapid progress many basic questions remain unanswered. Further study of Rasip1 as an essential factor for angiogenesis and tubulogenesis will provide a better understanding basic mechanisms underlying angiogenesis and lumen formation. Given that Rasip1 is only necessary during angiogenesis and is dispensable for established vasculature, targeting Rasip1 has potential as an anti-angiogenic agent.


  • Rasip1 is required for embryonic and postnatal sprouting and remodeling angiogenesis.
  • Embryonic subdermal and postnatal retinal vessels lacking Rasip1 display remodeling defects and vascular lumen diameter variability.
  • Integrity and stability of quiescent adult vessels does not require Rasip1.
  • Vascular permeability in adult mouse subdermal vessels does not require Rasip1.

Supplementary Material











We thank the following for mouse lines: Ralf Adams for Cdh5(PAC)-CreERT2, Tom Sato for Tie2-Cre, Janet Rossant for Flk1-eGFP and Thomas Carroll for Sox2-Cre and CAG-CreERT2. We thank Dr. Hiromi Yanagisawa for use of cell culture equipment. The authors would like to thank Stephen Fu and Katherine Speichinger for excellent technical assistance. We thank the TIG group, and the Carroll, Olson, MacDonald and Cleaver labs for invaluable discussions and assistance. Finally, we are very grateful to Dr. Bob Hammer and the UTSW Transgenic Core for help with generating the Rasip1 conditional mice.


This work was supported by NIH R01HL113498 to DMB, R01HL109604 to CM, R01HL105606 and R01HL108670 to GED, and CPRIT RP110405, R01HL113498 and R01DK079862 to OC.



The authors declare no competing or financial interests.


Most experiments were performed by Y.K. K.X. initiated experiments by crossing mouse lines and making initial observations. D.M.B. and S.F. carried out supportive experiments and D.M.B. finished key studies. K.T. and C.M. assisted with DIVAA implants. G.E.D. contributed to underlying ideas and analysis, contributed 3D in vitro data, and read manuscript critically. O.C. supervised the overall project and contributed to the analysis. Y.K., D.M.B and O.C. wrote the manuscript.


1. Sacharidou A, Stratman AN, Davis GE. Molecular mechanisms controlling vascular lumen formation in three-dimensional extracellular matrices. Cells Tissues Organs. 2012;195(1–2):122–143. doi: 10.1159/000331410. [PMC free article] [PubMed] [Cross Ref]
2. Bayless KJ, Davis GE. The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. J Cell Sci. 2002;115(Pt 6):1123–1136. [PubMed]
3. Sacharidou A, Koh W, Stratman AN, Mayo AM, Fisher KE, Davis GE. Endothelial lumen signaling complexes control 3D matrix-specific tubulogenesis through interdependent Cdc42- and MT1-MMP-mediated events. Blood. 2010;115(25):5259–5269. doi: 10.1182/blood-2009-11-252692. [PubMed] [Cross Ref]
4. Datta A, Bryant DM, Mostov KE. Molecular regulation of lumen morphogenesis. Curr Biol. 2011;21(3):R126–136. doi: 10.1016/j.cub.2010.12.003. S0960-9822(10)01589-7 [pii] [PMC free article] [PubMed] [Cross Ref]
5. Kesavan G, Sand FW, Greiner TU, Johansson JK, Kobberup S, Wu X, Brakebusch C, Semb H. Cdc42-mediated tubulogenesis controls cell specification. Cell. 2009;139(4):791–801. doi: 10.1016/j.cell.2009.08.049. [PubMed] [Cross Ref]
6. Zovein AC, Luque A, Turlo KA, Hofmann JJ, Yee KM, Becker MS, Fassler R, Mellman I, Lane TF, Iruela-Arispe ML. Beta1 integrin establishes endothelial cell polarity and arteriolar lumen formation via a Par3-dependent mechanism. Dev Cell. 2010;18(1):39–51. doi: 10.1016/j.devcel.2009.12.006. [PMC free article] [PubMed] [Cross Ref]
7. Xu K, Sacharidou A, Fu S, Chong DC, Skaug B, Chen ZF, Davis GE, Cleaver O. Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling. Developmental Cell. 2011:20. [PMC free article] [PubMed]
8. Koh W, Mahan RD, Davis GE. Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling. J Cell Sci. 2008;121(Pt 7):989–1001. doi: 10.1242/jcs.020693. jcs.020693 [pii] [PubMed] [Cross Ref]
9. Strilic B, Kucera T, Eglinger J, Hughes MR, McNagny KM, Tsukita S, Dejana E, Ferrara N, Lammert E. The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell. 2009;17(4):505–515. doi: 10.1016/j.devcel.2009.08.011. [PubMed] [Cross Ref]
10. Strilic B, Eglinger J, Krieg M, Zeeb M, Axnick J, Babal P, Muller DJ, Lammert E. Electrostatic cell-surface repulsion initiates lumen formation in developing blood vessels. Curr Biol. 2010;20(22):2003–2009. doi: 10.1016/j.cub.2010.09.061. [PubMed] [Cross Ref]
11. Mitin NY, Ramocki MB, Zullo AJ, Der CJ, Konieczny SF, Taparowsky EJ. Identification and characterization of rain, a novel Ras-interacting protein with a unique subcellular localization. J Biol Chem. 2004;279(21):22353–22361. [PubMed]
12. Xu K, Chong DC, Rankin SA, Zorn AM, Cleaver O. Rasip1 is required for endothelial cell motility, angiogenesis and vessel formation. Dev Biol. 2009;329(2):269–279. doi: 10.1016/j.ydbio.2009.02.033. [PMC free article] [PubMed] [Cross Ref]
13. Xu K, Cleaver O. Tubulogenesis during blood vessel formation. Seminars in cell & developmental biology. 2011;22(9):993–1004. doi: 10.1016/j.semcdb.2011.05.001. [PMC free article] [PubMed] [Cross Ref]
14. Wilson CW, Parker LH, Hall CJ, Smyczek T, Mak J, Crow A, Posthuma G, De Maziere A, Sagolla M, Chalouni C, Vitorino P, Roose-Girma M, Warming S, Klumperman J, Crosier PS, Ye W. Rasip1 regulates vertebrate vascular endothelial junction stability through Epac1-Rap1 signaling. Blood. 2013;122(22):3678–3690. doi: 10.1182/blood-2013-02-483156. [PubMed] [Cross Ref]
15. Post A, Pannekoek WJ, Ross SH, Verlaan I, Brouwer PM, Bos JL. Rasip1 mediates Rap1 regulation of Rho in endothelial barrier function through ArhGAP29. Proc Natl Acad Sci U S A. 2013;110(28):11427–11432. doi: 10.1073/pnas.1306595110. [PubMed] [Cross Ref]
16. Post A, Pannekoek WJ, Ponsioen B, Vliem MJ, Bos JL. Rap1 Spatially Controls ArhGAP29 To Inhibit Rho Signaling during Endothelial Barrier Regulation. Molecular and cellular biology. 2015;35(14):2495–2502. doi: 10.1128/MCB.01453-14. [PMC free article] [PubMed] [Cross Ref]
17. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376(6535):62–66. doi: 10.1038/376062a0. [PubMed] [Cross Ref]
18. Hayashi S, Lewis P, Pevny L, McMahon AP. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech Dev. 2002;119(Suppl 1):S97–S101. [PubMed]
19. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001;230(2):230–242. doi: 10.1006/dbio.2000.0106. [PubMed] [Cross Ref]
20. Monvoisin A, Alva JA, Hofmann JJ, Zovein AC, Lane TF, Iruela-Arispe ML. VE-cadherin-CreERT2 transgenic mouse: a model for inducible recombination in the endothelium. Dev Dyn. 2006;235(12):3413–3422. doi: 10.1002/dvdy.20982. [PubMed] [Cross Ref]
21. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol. 2002;244(2):305–318. doi: 10.1006/dbio.2002.0597. [PubMed] [Cross Ref]
22. Barry DM, Xu K, Meadows SM, Zheng Y, Norden PR, Davis GE, Cleaver O. Cdc42 is required for cytoskeletal support of endothelial cell adhesion during blood vessel formation in mice. Development. 2015;142(17):3058–3070. doi: 10.1242/dev.125260. [PubMed] [Cross Ref]
23. Pitulescu ME, Schmidt I, Benedito R, Adams RH. Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. Nature protocols. 2010;5(9):1518–1534. doi: 10.1038/nprot.2010.113. [PubMed] [Cross Ref]
24. Stratman AN, Davis MJ, Davis GE. VEGF and FGF prime vascular tube morphogenesis and sprouting directed by hematopoietic stem cell cytokines. Blood. 2011;117(14):3709–3719. doi: 10.1182/blood-2010-11-316752. [PubMed] [Cross Ref]
25. Chong DC, Koo Y, Xu K, Fu S, Cleaver O. Stepwise arteriovenous fate acquisition during mammalian vasculogenesis. Dev Dyn. 2011;240(9):2153–2165. doi: 10.1002/dvdy.22706. [PMC free article] [PubMed] [Cross Ref]
26. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Developmental biology. 2001;230(2):230–242. doi: 10.1006/dbio.2000.0106. [PubMed] [Cross Ref]
27. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Luthi U, Barberis A, Benjamin LE, Makinen T, Nobes CD, Adams RH. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010;465(7297):483–486. doi: 10.1038/nature09002. [PubMed] [Cross Ref]
28. Stahl A, Connor KM, Sapieha P, Chen J, Dennison RJ, Krah NM, Seaward MR, Willett KL, Aderman CM, Guerin KI, Hua J, Lofqvist C, Hellstrom A, Smith LE. The mouse retina as an angiogenesis model. Investigative ophthalmology & visual science. 2010;51(6):2813–2826. doi: 10.1167/iovs.10-5176. [PMC free article] [PubMed] [Cross Ref]
29. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6):1163–1177. [PMC free article] [PubMed]
30. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomaki A, Aranda E, Miura N, Yla-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nature cell biology. 2011;13(10):1202–1213. doi: 10.1038/ncb2331. [PMC free article] [PubMed] [Cross Ref]
31. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature. 2008;454(7204):656–660. doi: 10.1038/nature07083. [PubMed] [Cross Ref]
32. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, Peri F, Wilson SW, Ruhrberg C. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010;116(5):829–840. doi: 10.1182/blood-2009-12-257832. [PubMed] [Cross Ref]
33. Radu M, Chernoff J. An in vivo assay to test blood vessel permeability. Journal of visualized experiments : JoVE. 2013;(73):e50062. doi: 10.3791/50062. [PubMed] [Cross Ref]
34. Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 2010;87(2):262–271. doi: 10.1093/cvr/cvq105. [PMC free article] [PubMed] [Cross Ref]
35. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol. 2003;162(5):1431–1439. doi: 10.1016/S0002-9440(10)64276-9. [PubMed] [Cross Ref]
36. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003;114(2):171–180. [PubMed]
37. Napoli C, Giordano A, Casamassimi A, Pentimalli F, Ignarro LJ, De Nigris F. Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer. Int J Cancer. 2011;128(7):1505–1508. doi: 10.1002/ijc.25743. [PubMed] [Cross Ref]
38. Ando K, Fukuhara S, Moriya T, Obara Y, Nakahata N, Mochizuki N. Rap1 potentiates endothelial cell junctions by spatially controlling myosin II activity and actin organization. J Cell Biol. 2013;202(6):901–916. doi: 10.1083/jcb.201301115. [PMC free article] [PubMed] [Cross Ref]
39. Outtz HH, Tattersall IW, Kofler NM, Steinbach N, Kitajewski J. Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice. Blood. 2011;118(12):3436–3439. doi: 10.1182/blood-2010-12-327015. [PubMed] [Cross Ref]
40. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H, Betsholtz C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445(7129):776–780. [PubMed]
41. Murakami M. Signaling required for blood vessel maintenance: molecular basis and pathological manifestations. International journal of vascular medicine. 2012;2012:293641. doi: 10.1155/2012/293641. [PMC free article] [PubMed] [Cross Ref]